Health-Oriented Protocol for Epidermal Radiodermatitis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational protocol aims to characterize radiation-induced dermatitis in adults undergoing radiotherapy for head and neck or pelvic cancers. It will collect data on intrinsic and extrinsic factors that may influence RID severity, such as patient demographics, comorbidities, radiation technique, dose, and infection status. The study involves patients receiving exclusive radiotherapy or concurrent chemoradiotherapy and follows them under standard care to identify patterns and potential predictors of RID. Results may help guide closer monitoring and supportive care to minimize skin toxicity during cancer treatment. The investigation is conducted at a single tertiary center in Rome, led by Fondazione Policlinico Universitario Agostino Gemelli IRCCS.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients aged ≥18 years
* with head and neck or pelvic malignancies
* undergoing either exclusive radiotherapy or concurrent chemoradiotherapy will be included, following signed informed consent.

Exclusion Criteria:

* Pediatric patients,
* patients with malignancies outside the head and neck or pelvic regions,
* patients who have not yet started or have already completed exclusive radiotherapy or concurrent chemoradiotherapy

Where it's running

• Fondazione Policlinico Universitario Gemelli IRCCS
  Roma, Rm, Italy Recruiting

Study contacts

• Principal investigator: danilo pasini — Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• Study coordinator: danilo pasini
• Email: danilo.pasini@policlinicogemelli.it
• Phone: +390630158372

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• High-precision detection of leftover cancer using a liquid-biopsy platform (SHERLOCK)

  This project will test whether sensitive blood and other fluid tests for circulating tumor DNA can find leftover cancer (minimal residual disease) in adults treated with curative intent for breast, lung, melanoma, gynecologic, or genitourinary cancers.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT07524114

• Riluzole to prevent thinking and memory problems during chemotherapy

  This pilot trial tests whether riluzole can prevent thinking and memory problems in adults with cancer receiving anthracycline- or platinum-based chemotherapy.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT07447050

• Radiotherapy for Head and Neck Cancer with Simultaneous Integrated Boost

  This study is testing a new type of radiation therapy for people with head and neck cancer to see if it helps them live longer and feel better while causing fewer side effects.

  Recruiting Wuerzburg University Hospital · Würzburg, Bavaria · NCT06831903

• Using brodalumab to treat immune-related side effects from cancer therapy

  This study is testing if brodalumab can help cancer patients who are having immune-related side effects from their immunotherapy treatment feel better.

  Recruiting Phase 1 Columbia University · New York, New York · NCT06673329

• Evaluating fatigue and molecular mechanisms in cancer patients undergoing combined chemotherapy and radiation therapy

  This study is testing how fatigue affects cancer patients getting both chemotherapy and radiation therapy, and whether certain genes and molecules are linked to how tired they feel during treatment.

  Recruiting University of California, San Francisco · San Francisco, California · NCT06633224

• Using Riluzole to Help Breast Cancer Survivors with Cognitive Issues

  This study is testing if the medication riluzole can help breast cancer survivors who are having trouble with thinking and memory feel better.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT06580002

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.